Other was the largest of Thermo Fisher Scientific Inc.’s 4 reported lines in fiscal 2025, at $22.32B — 51% of $43.84B.
| Geography | FY 2009 | FY 2010 | FY 2012 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | — | — | — | $22.32B | |||||||
| North America | $24.59B | $22.76B | — | — | |||||||
| United States | — | — | $21.76B | — | |||||||
| Revenues | — | — | — | — | |||||||
| Europe | $10.76B | $10.74B | — | $11.83B | |||||||
| All Other Countries | — | — | — | — | |||||||
| Asia-Pacific | $8.12B | $7.87B | $7.96B | $8.10B | |||||||
| Asia Pacific | — | — | — | — | |||||||
| China | — | — | — | — | |||||||
| Other Regions | $1.44B | $1.48B | $1.56B | $1.60B | |||||||
| Total | $44.92B | $42.86B | $31.27B | $43.84B |
In fiscal 2025, which ended December 31, 2025, the 4 regions Thermo Fisher Scientific Inc. reported in this breakdown added up to $43.84B. The regions reported changed from fiscal 2024, so the total is not directly comparable with the $31.27B reported that year. Other was the largest region, at $22.32B or 50.9% of the total, followed by Europe ($11.83B, 27.0%) and Asia-Pacific ($8.10B, 18.5%). Together, the two largest regions made up 77.9% of this total.
Compared with fiscal 2024, Other Regions grew the fastest, rising 2.3% to $1.60B. Because regions were added or dropped between the two years, part of this reflects how Thermo Fisher Scientific Inc. regrouped its reporting.
Other was first reported as a separate region in fiscal 2025. The table also keeps 6 regions that Thermo Fisher Scientific Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 11 fiscal years between 2009 and 2025, as reported in Thermo Fisher Scientific Inc.'s annual filings.
Consumables was the largest of Thermo Fisher Scientific Inc.’s 3 reported lines in fiscal 2025, at $18.66B — 42% of $44.56B.
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Consumables | $20.62B | $17.60B | $17.59B | $18.66B | ||||||
| Product | — | — | — | — | ||||||
| Service Revenues | $16.37B | $17.61B | $17.85B | $18.59B | ||||||
| Service | — | — | — | — | ||||||
| Instruments | $7.92B | $7.65B | $7.45B | $7.30B | ||||||
| Total | $44.92B | $42.86B | $42.88B | $44.56B |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines Thermo Fisher Scientific Inc. reported in this breakdown added up to $44.56B. That was up 3.9% from $42.88B in fiscal 2024. Consumables was the largest revenue line, at $18.66B or 41.9% of the total, followed by Service Revenues ($18.59B, 41.7%) and Instruments ($7.30B, 16.4%). Together, the two largest revenue lines made up 83.6% of this total.
Compared with fiscal 2024, Consumables grew the fastest, rising 6.1% to $18.66B. Instruments fell the most, down 1.9% to $7.30B. Over fiscal 2022 to 2025, revenue across these revenue lines went from $44.92B to $44.56B, a compound annual decline of 0.3%. Consumables' share of the total fell from 45.9% to 41.9% over the same years.
The table also keeps 2 revenue lines that Thermo Fisher Scientific Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Thermo Fisher Scientific Inc.'s annual filings.
Pharma Services was the largest of Thermo Fisher Scientific Inc.’s 13 reported lines in fiscal 2024, at $6.69B — 22% of $31.08B.
| Subsegments | FY 2024 |
|---|---|
| Pharma Services | $6.69B |
| Biosciences | $4.19B |
| Chromatography & Mass Spectrometry | $3.28B |
| Electron Microscopy | $2.87B |
| Genetic Sciences | $2.79B |
| Bioproduction | $2.65B |
| Laboratory Products | $2.53B |
| Healthcare Market Channel | $1.76B |
| Chemical Analysis | $1.32B |
| Clinical Diagnostics | $1.06B |
| Immunodiagnostics | $864.00M |
| Microbiology | $633.00M |
| Transplant Diagnostics | $454.00M |
| Total | $31.08B |
In fiscal 2024, which ended December 31, 2024, the 13 segments Thermo Fisher Scientific Inc. reported in this breakdown added up to $31.08B. Pharma Services was the largest segment, at $6.69B or 21.5% of the total, followed by Biosciences ($4.19B, 13.5%) and Chromatography & Mass Spectrometry ($3.28B, 10.5%). Together, the two largest segments made up 35.0% of this total.
This breakdown covers every fiscal year from 2024 to 2024, as reported in Thermo Fisher Scientific Inc.'s annual filings.
Thermo Fisher Scientific Inc. (TMO) breaks its revenue down by region, revenue line and segment. In fiscal 2025, its largest region was Other, with $22.32B or 50.9% of the total, followed by Europe at $11.83B (27.0%).
Other was Thermo Fisher Scientific Inc.'s largest region in fiscal 2025, with $22.32B in revenue, 50.9% of the $43.84B reported across its 4 regions.
Consumables was Thermo Fisher Scientific Inc.'s largest revenue line in fiscal 2025, with $18.66B in revenue, 41.9% of the $44.56B reported across its 3 revenue lines.
Pharma Services was Thermo Fisher Scientific Inc.'s largest segment in fiscal 2024, with $6.69B in revenue, 21.5% of the $31.08B reported across its 13 segments.
Of the Thermo Fisher Scientific Inc. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Consumables grew the fastest, rising 6.1% from $17.59B to $18.66B.
Every figure is taken from Thermo Fisher Scientific Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2009 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.